Comparative Pharmacology
Head-to-head clinical analysis: SULFABID versus SULFALOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFABID versus SULFALOID.
SULFABID vs SULFALOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate and thereby inhibiting bacterial folate synthesis.
Sulfaloid is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production in susceptible bacteria.
500 mg orally every 12 hours for 10-14 days.
500 mg orally every 12 hours for 7-10 days.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 6-8 hours in adults with normal renal function (ClCr >90 mL/min); prolonged to 12-20 hours in moderate renal impairment (ClCr 30-50 mL/min) and >30 hours in severe renal impairment (ClCr <30 mL/min).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary: 5-10% as metabolites. Fecal: <5%.
Renal: 70% (unchanged via glomerular filtration and tubular secretion); Biliary/fecal: 20% (conjugated metabolites); 10% metabolized in liver to inactive acetylated derivatives.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)